Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.
Bottom Line: The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties.Our results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide.Identification of the differential effects of these compounds will enable targeting of such compounds into the appropriate clinical setting.
Affiliation: Division of Oncology, St. George's Hospital Medical School, Tooting, London SW17 0RE, UK. firstname.lastname@example.orgShow MeSH
Related in: MedlinePlus
Mentions: In order to determine whether a thalidomide analogue with potent anti-angiogenic activity in vitro could be beneficial in a clinical cancer setting, we tested the most potent analogue IMiD-1, in an in vivo tumour challenge model. Daily administration of IMiD-1 (10 or 50 mg kg−1, i.p.) was found to significantly reduce the tumour growth rates (P<0.05) in nude mice and histological examination revealed drug-treated tumours to contain vast regions of necrotic tissue (Figure 5Figure 5
Affiliation: Division of Oncology, St. George's Hospital Medical School, Tooting, London SW17 0RE, UK. email@example.com